DMR-001, a potentially best-in-class mutant calreticulin ('mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human ...

FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability ...

Interest rate sensitivity: Lower interest rates typically benefit small-cap companies more than their large-cap counterparts.

Fundsmith, an investment management firm based in London, has released its annual 2025 investor letter for its “Fundsmith ...

Catastrophe bond funds in the UCITS format closed out a stunning year of growth to reach a significant $19.12 billion of ...

Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...

In 2025, over 656,000 learners passed the National Senior Certificate. That figure carries the effort of teachers, learners ...

The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to ...

The Yale Chief Executive Leadership Institute highlights the top performers of 2025 and the top leaders to watch in 2026.

The bad news for Philadelphia is that these advantages are being squandered by leadership that can’t translate assets into ...

SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...

Discover how the economy impacts employability and explore essential skills that enhance job prospects, from technical to ...